Katelyn is a writer with CNET covering artificial intelligence, including chatbots, image and video generators. Her work explores how new AI technology is infiltrating our lives, shaping the content ...
Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative breast cancer (TNBC), but could be heading for use in previously untreated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback